ECSP14009619A - Compuestos novedosos de benzopirano, composiciones y usos de los mismos - Google Patents

Compuestos novedosos de benzopirano, composiciones y usos de los mismos

Info

Publication number
ECSP14009619A
ECSP14009619A ECIEPI20149619A ECPI201409619A ECSP14009619A EC SP14009619 A ECSP14009619 A EC SP14009619A EC IEPI20149619 A ECIEPI20149619 A EC IEPI20149619A EC PI201409619 A ECPI201409619 A EC PI201409619A EC SP14009619 A ECSP14009619 A EC SP14009619A
Authority
EC
Ecuador
Prior art keywords
compositions
methyl
estrogen
benzopyrane
novelty
Prior art date
Application number
ECIEPI20149619A
Other languages
English (en)
Inventor
Cyrus Harmon
Leslie Gallagher
David Myles
Peter Kushner
Original Assignee
Strada Design Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48613277&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14009619(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Strada Design Ltd filed Critical Strada Design Ltd
Publication of ECSP14009619A publication Critical patent/ECSP14009619A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

Se proveen compuestos de benzopirano con fuerte actividad anti-estrogénica y en esencia ninguna actividad estrogénica, que son OP-1038, que es 3-(4-hidroxifenil)-4-metil-2-(4-{2-[(3R)-3-metil-pirrolidin-1-il]etoxi}fenil)-2H-cromen-7-ol, y OP-1074, que es (2S)-3-(4-hidroxifenil)-4-metil-2-(4-{2-[(3R)-3-metilpirrolidin-1-il]etoxi}fenil)-2H-cromen-7-ol. OP-1074 es un anti-estrógeno puro cuando es probado en el modo agonista y un anti-estrógeno completo cuando se prueba en el modo antagonista. Estos compuestos son útiles para el tratamiento o prevención de una variedad de condiciones que son modulados a través del receptor de estrógeno en mamíferos incluyendo humanos.
ECIEPI20149619A 2011-12-16 2014-07-16 Compuestos novedosos de benzopirano, composiciones y usos de los mismos ECSP14009619A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161576890P 2011-12-16 2011-12-16

Publications (1)

Publication Number Publication Date
ECSP14009619A true ECSP14009619A (es) 2015-09-30

Family

ID=48613277

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20149619A ECSP14009619A (es) 2011-12-16 2014-07-16 Compuestos novedosos de benzopirano, composiciones y usos de los mismos

Country Status (27)

Country Link
US (2) US9018244B2 (es)
EP (1) EP2791128A4 (es)
JP (1) JP2015505856A (es)
KR (1) KR20140103335A (es)
CN (1) CN104169266A (es)
AP (1) AP2014007657A0 (es)
AU (1) AU2012353660A1 (es)
BR (1) BR112014014767A2 (es)
CA (1) CA2857061A1 (es)
CL (1) CL2014001533A1 (es)
CR (1) CR20140259A (es)
CU (1) CU20140066A7 (es)
DO (1) DOP2014000135A (es)
EA (1) EA201490897A1 (es)
EC (1) ECSP14009619A (es)
HK (1) HK1199246A1 (es)
IL (1) IL233118A0 (es)
MA (1) MA35722B1 (es)
MD (1) MD20140054A2 (es)
MX (1) MX2014007198A (es)
NI (1) NI201400057A (es)
PE (1) PE20150099A1 (es)
PH (1) PH12014501237A1 (es)
SG (1) SG11201402564QA (es)
TN (1) TN2014000243A1 (es)
WO (1) WO2013090921A1 (es)
ZA (1) ZA201404733B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 ***受体调节剂及其用途
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN104725333A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种新的氮杂环庚烷衍生物的制备方法
WO2015136016A2 (en) * 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
SG11201607339VA (en) * 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
AU2016301195B2 (en) 2015-08-06 2022-09-01 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive T-cell therapy associated adverse inflammatory responses
KR20180071274A (ko) 2015-10-01 2018-06-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
UA122348C2 (uk) 2015-10-27 2020-10-26 Сан Фарма Адвансед Ресьорч Компані Лімітед Нові гетероциклічні антиестрогени
MX2018007079A (es) 2015-12-09 2018-11-12 The Board Of Trustees Of Univ Of Illinois Reguladores a la baja del receptor de estrogeno selectivo de benzotiofeno.
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
JP2019520379A (ja) 2016-07-01 2019-07-18 ジー１ セラピューティクス， インコーポレイテッド ピリミジン系の抗増殖剤
PL3525774T3 (pl) 2016-10-11 2022-04-25 Duke University Leczenie lazofoksyfenem raka piersi er+
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US11311609B2 (en) 2017-02-08 2022-04-26 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
US10208011B2 (en) 2017-02-10 2019-02-19 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
RU2019142591A (ru) 2017-06-29 2021-07-29 Г1 Терапьютикс, Инк. Морфологические формы g1t38 и способы их получения
BR112020007576A2 (pt) 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
WO2019161157A1 (en) 2018-02-16 2019-08-22 Constellation Pharmceuticals, Inc. P300/cbp hat inhibitors
AU2019220662A1 (en) 2018-02-16 2020-09-03 Constellation Pharmaceuticals, Inc. P300/CBP HAT inhibitors
WO2019199891A1 (en) 2018-04-10 2019-10-17 Duke University Lasofoxifene treatment of breast cancer
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
CA3131383A1 (en) 2019-02-27 2020-09-03 Constellation Pharmaceuticals, Inc. P300/cbp hat inhibitors and methods for their use
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
JP2022541938A (ja) 2019-07-22 2022-09-28 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 選択的エストロゲン受容体分解剤
US20220331304A1 (en) 2019-07-29 2022-10-20 Constellation Pharmaceuticals, Inc. Compounds for use in treating neurological disorders
CN113045546A (zh) * 2021-03-25 2021-06-29 浙江天宇药业股份有限公司 一种吡咯替尼杂质、其制备方法及用途
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5686465A (en) 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
US5254568A (en) 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5446061A (en) 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5416098A (en) 1993-12-30 1995-05-16 Zymogenetics, Inc. Method for treating dermatitis and related conditions
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5446071A (en) 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5637598A (en) 1994-11-18 1997-06-10 Eli Lilly And Company Methods of inhibiting bone loss
US5980938A (en) 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
WO1999002512A1 (en) 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
PL344534A1 (en) 1997-11-28 2001-11-05 Innogenetics Nv Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6262270B1 (en) 1998-08-14 2001-07-17 Schering Corporation Enantioselective synthesis
CA2340343C (en) 1998-08-14 2007-04-24 Schering Corporation Enantioselective synthesis
AR021719A1 (es) 1998-12-18 2002-07-31 Schering Corp Composicion farmaceutica oral antiestrogenica.
US6638727B1 (en) 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
HU230543B1 (hu) 1999-07-06 2016-11-28 Endorecherche, Inc. Inzulinrezisztencia kezelésére és/vagy megakadályozására szolgáló gyógyszerkészítmények
AU7896100A (en) 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
KR20020073566A (ko) 2000-01-28 2002-09-27 앙도르쉐르슈 인코포레이티드 에스트로겐과 배합된 선택적인 에스트로겐 수용체 조절자
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
EP1515748A4 (en) 2001-11-14 2006-04-12 David A Sirbasku ANTIESTROGEN AND IMMUNOMODULATOR COMBINATIONS FOR THE TREATMENT OF BREAST CANCER
ES2350446T3 (es) 2002-04-24 2011-01-24 MERCK SHARP & DOHME CORP. Moduladores de los receptores de estrógenos.
WO2004091488A2 (en) 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
CN106038572A (zh) 2004-10-20 2016-10-26 恩多研究公司 性甾体前体单独或与选择性***受体调节剂联合用于预防和治疗绝经后女性的性功能障碍
BRPI0703735A2 (pt) 2007-08-29 2009-09-15 Endorech Inc aperfeiçoamento em composto opticamente ativo ou sal farmaceuticamente aceitável do mesmo e composição contendo o referido composto
WO2009039344A1 (en) * 2007-09-21 2009-03-26 Harry Fisch Treatment of migraine headaches using antiestrogens
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
SI3124481T1 (en) 2010-02-16 2018-06-29 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and their use
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 ***受体调节剂及其用途
WO2011156908A1 (en) 2010-06-16 2011-12-22 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
DK3533792T3 (da) 2012-06-07 2021-06-28 Aragon Pharmaceuticals Inc Krystallinske former af en androgenreceptormodulator
PE20190845A1 (es) 2012-07-27 2019-06-17 Aragon Pharmaceuticals Inc Metodos para determinar resistencia a terapia de receptor de androgeno
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته

Also Published As

Publication number Publication date
MA35722B1 (fr) 2014-12-01
CN104169266A (zh) 2014-11-26
PE20150099A1 (es) 2015-01-30
ZA201404733B (en) 2016-04-28
NI201400057A (es) 2014-10-01
MX2014007198A (es) 2014-10-13
CA2857061A1 (en) 2013-06-20
EP2791128A4 (en) 2015-04-22
CL2014001533A1 (es) 2014-10-17
US20150197506A1 (en) 2015-07-16
US20130178445A1 (en) 2013-07-11
AU2012353660A1 (en) 2014-06-12
IL233118A0 (en) 2014-08-03
SG11201402564QA (en) 2014-09-26
PH12014501237A1 (en) 2014-09-08
HK1199246A1 (en) 2015-06-26
KR20140103335A (ko) 2014-08-26
EA201490897A1 (ru) 2015-03-31
CR20140259A (es) 2014-08-21
MD20140054A2 (ro) 2014-10-31
EP2791128A1 (en) 2014-10-22
AP2014007657A0 (en) 2014-05-31
TN2014000243A1 (fr) 2015-09-30
US9018244B2 (en) 2015-04-28
CU20140066A7 (es) 2014-10-02
WO2013090921A1 (en) 2013-06-20
JP2015505856A (ja) 2015-02-26
DOP2014000135A (es) 2014-08-31
BR112014014767A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
ECSP14009619A (es) Compuestos novedosos de benzopirano, composiciones y usos de los mismos
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
DOP2017000038A (es) 2-(morfolin-4-il)-1,7-naftiridinas
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
GT201400111A (es) Triazolopiridinas sustituidas
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
CL2012003226A1 (es) Compuestos derivados de 5-fluoro-1h-pirazolopiridina ; procedimiento de preparacion de estos; composicion framaceutica que los comprende; y su uso en el tratamiento de enfermedades cardiovasculares, sexuales y metabolicas.
BRPI0803374A2 (pt) compostos polihidróxi como agentes de extinção de polimerização
PE20141821A1 (es) Composiciones herbicidas que contienen bentazon y el inhibidor als y el inhibidor accasa
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CO6761389A2 (es) Inhibidores de nampt y rock
ECSP099502A (es) 4-fenil-piran-3,5-dionas, 4-fenil-tiopiran-3,5-dionas y ciclohexantrionas como nuevos herbicidas
ECSP13012590A (es) Composiciones bioactivas de chromobacterium y metabolitos
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
IN2015DN00885A (es)
DOP2014000098A (es) 2-tiopirimidinonas
CL2011000570A1 (es) Compuestos derivados de 3-(4-ciano-fenil)-pirazol-5-carboxamida, moduladores del receptor de progesterona; composicion farmaceutica; y su uso para el tratamiento de endometriosis, fibromiomas uterinos, dismenorrea primaria o secundaria, entre otras.
CL2013000733A1 (es) Compuestos derivados de arilalquilimidazol, moduladores selectivos de receptores alfa 2 adrenergicos; y composicion farmaceutica que los comprende.
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
AR099500A1 (es) Composición para el desmucilaginado enzimático de aceite
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CL2010000804A1 (es) Compuestos derivados de 3-(1 h-pirrol-2-il-metil)-1 ,3-dihidro-2h-indol-2-ona; procedimientos de preparación de dichos compuestos; composición farmacéutica y combinación farmacéutica que los comprende; y su uso para el tratamiento de cáncer.
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
PE20150371A1 (es) Indolcarbonitrilos como moduladores selectivos del receptor de androgeno